59 related articles for article (PubMed ID: 20430774)
41. Temsirolimus.
Schulze M; Stock C; Zaccagnini M; Teber D; Rassweiler JJ
Recent Results Cancer Res; 2014; 201():393-403. PubMed ID: 24756806
[TBL] [Abstract][Full Text] [Related]
42. [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].
Mounier N; Vignot S; Spano JP
Bull Cancer; 2006 Nov; 93(11):1139-43. PubMed ID: 17145584
[TBL] [Abstract][Full Text] [Related]
43. Temsirolimus.
Ma WW; Jimeno A
Drugs Today (Barc); 2007 Oct; 43(10):659-69. PubMed ID: 17987219
[TBL] [Abstract][Full Text] [Related]
44. Temsirolimus.
Stock C; Zaccagnini M; Schulze M; Teber D; Rassweiler JJ
Recent Results Cancer Res; 2010; 184():189-97. PubMed ID: 20072839
[TBL] [Abstract][Full Text] [Related]
45. Temsirolimus: CCI 779, CCI-779, cell cycle inhibitor-779.
Drugs R D; 2004; 5(6):363-7. PubMed ID: 15563243
[TBL] [Abstract][Full Text] [Related]
46. Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects.
Bouabdallah K; Ribrag V; Terriou L; Soria JC; Delarue R
Curr Opin Oncol; 2013 Mar; 25 Suppl 2():S1-12. PubMed ID: 23388840
[TBL] [Abstract][Full Text] [Related]
47. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.
Lo Muzio L; Arena C; Troiano G; Villa A
Oral Dis; 2018 Mar; 24(1-2):144-171. PubMed ID: 29480626
[TBL] [Abstract][Full Text] [Related]
48. Practical management of everolimus-related toxicities in patients with advanced solid tumors.
Grünwald V; Weikert S; Pavel ME; Hörsch D; Lüftner D; Janni W; Geberth M; Weber MM
Onkologie; 2013; 36(5):295-302. PubMed ID: 23689226
[TBL] [Abstract][Full Text] [Related]
49. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis.
Gomez-Fernandez C; Garden BC; Wu S; Feldman DR; Lacouture ME
Eur J Cancer; 2012 Feb; 48(3):340-6. PubMed ID: 22206873
[TBL] [Abstract][Full Text] [Related]
50. Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: a case report and literature review.
Raimondi A; Colombo F; Pintarelli G; Morosi C; Renne SL; Frezza AM; Saponara M; Dei Tos AP; Mazzocchi A; Provenzano S; Casali PG; Stacchiotti S
Anticancer Drugs; 2018 Jul; 29(6):589-595. PubMed ID: 29668485
[TBL] [Abstract][Full Text] [Related]
51. [Pharmacokinetics and impaired organic functions].
Chatelut E
Bull Cancer; 2011 Nov; 98(11):1347-54. PubMed ID: 22024557
[TBL] [Abstract][Full Text] [Related]
52. Hyperglycemic-inducing neoadjuvant agents used in treatment of solid tumors: a review of the literature.
Hershey DS; Bryant AL; Olausson J; Davis ED; Brady VJ; Hammer M
Oncol Nurs Forum; 2014 Nov; 41(6):E343-54. PubMed ID: 25355030
[TBL] [Abstract][Full Text] [Related]
53. Neocarzinostatin (NSC 157365) a new cancerostatic compound.
Legha SS; Von Hoff DD; Rozencweig M; Abraham D; Slavik M; Muggia M
Oncology; 1976; 33(5-6):265-70. PubMed ID: 141012
[TBL] [Abstract][Full Text] [Related]
54. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
Fujisaka Y; Yamada Y; Yamamoto N; Horiike A; Tamura T
Jpn J Clin Oncol; 2010 Aug; 40(8):732-8. PubMed ID: 20430774
[TBL] [Abstract][Full Text] [Related]
55. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
Malizzia LJ; Hsu A
Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
[TBL] [Abstract][Full Text] [Related]
56. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.
Boni JP; Hug B; Leister C; Sonnichsen D
Semin Oncol; 2009 Dec; 36 Suppl 3():S18-25. PubMed ID: 19963096
[TBL] [Abstract][Full Text] [Related]
57. Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor.
Peuvrel L; Quéreux G; Brocard A; Saint-Jean M; Dréno B
Dermatology; 2012; 224(3):204-8. PubMed ID: 22614575
[TBL] [Abstract][Full Text] [Related]
58. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.
De Masson A; Fouchard N; Méry-Bossard L; Dauendorffer JN
Dermatology; 2011; 223(1):4-8. PubMed ID: 21846963
[TBL] [Abstract][Full Text] [Related]
59. Temsirolimus: in advanced renal cell carcinoma.
Simpson D; Curran MP
Drugs; 2008; 68(5):631-8. PubMed ID: 18370442
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
